IP Library › Granted Patent US 12,440,553
Granted Patent B2
US 12,440,553 · App. 17/523,813 · Granted Oct 14, 2025

Multivalent carriers and related vaccine compositions

Inventors: Alexander A. Cohen (Pasadena, CA); Pamela J. Bjorkman (Altadena, CA)
Assignee: California Institute of Technology
A61K39/215A61K39/385A61K39/39A61P31/14A61P37/04C07K14/165A61K2039/5258A61K2039/53A61K2039/55505A61K2039/55555A61K2039/70C12N2770/20022C12N2770/20034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,553
App. No.
17/523,813
Granted
Oct 14, 2025
Kind
B2
Abstract

Disclosed herein include multivalent carriers comprising a plurality of heterologous coronavirus proteins antigens derived from different coronaviruses. The multivalent carriers herein described can elicit heterologous binding and neutralization properties against coronoviruses that differ from the coronoviruses from which the coronavirus antigens are derived to produce the multivalent carriers. Also provided herein include vaccine compositions comprising the multivalent carriers and related methods using the vaccine compositions in various therapeutic and prophylactic applications.

Claims (32)

1. A vaccine composition, comprising a multivalent carrier associated with a plurality of coronavirus antigens, wherein the plurality of coronavirus antigens comprises a first coronavirus antigen of a first coronavirus strain and a second coronavirus antigen of a second coronavirus strain that is different from the first coronavirus strain,

wherein the first coronavirus antigen and the second coronavirus antigen each comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12 and the amino acid sequences of the first and second coronavirus antigens are different from one another, and

wherein the multivalent carrier comprises a self-assembling nanoparticle.

2. The vaccine composition of claim 1 , wherein the plurality of coronavirus antigens are displayed on the surface of the multivalent carrier.

3. The vaccine composition of claim 1 , wherein the first coronavirus antigen, the second coronavirus antigen, or both comprise a coronavirus S protein.

4. The vaccine composition of claim 1 , wherein the first coronavirus antigen and the second coronavirus antigen each comprise (1) an amino acid sequence having at least 85%, 90%, 95%, 98%, or 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12; or (2) an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12.

5. The vaccine composition of claim 1 , wherein the plurality of coronavirus antigens further comprise at least a third coronavirus antigen of a third coronavirus strain and a fourth coronavirus antigen of a fourth coronavirus strain, and wherein the first, second, third and fourth coronavirus strains are different from one another.

6. The vaccine composition of claim 1 , comprise three, four, five, six, seven, or eight coronavirus S protein RBDs, and wherein each of the plurality of coronavirus S protein RBDs is from a coronavirus strain different from another.

7. The vaccine composition of claim 1 , wherein the first coronavirus strain and the second coronavirus strain are in the genus of Beta- coronavirus.

8. The vaccine composition of claim 1 , wherein the first coronavirus strain, the second coronavirus strain, or both are selected from the group consisting of: SARS-COV, SARS-COV-2, WIV1, SHC014, Rf1, RmYN02, pang17, RaTG13, Rs4081, Yun11, BM-4831, and BtKY72.

9. The vaccine composition of claim 1 , further comprising an adjuvant.

10. The vaccine composition of claim 9 , wherein the adjuvant is selected from the group consisting of: aluminum hydroxide, alhydrogel, MF59, AS03, Freund's adjuvant, CpG, Poly I:C, glucopyranosyl lipid A, flagellin, resiquimod, and a combination thereof.

11. A method of stimulating an immune response in a subject in need thereof, comprising: administering to the subject a pharmaceutically effective amount of the vaccine composition of claim 1 , thereby stimulating an immune response in the subject.

12. A method for treating or preventing a coronavirus infection in a subject in need thereof, comprising: administering to the subject a pharmaceutically effective amount of the vaccine composition of claim 1 , thereby treating or preventing the coronavirus infection in the subject.

13. A method of treating or preventing a disease or disorder caused by a coronavirus infection in a subject in need thereof, comprising: administering to the subject a pharmaceutically effective amount of the vaccine composition of claim 1 , thereby treating or preventing the disease or disorder caused by the coronavirus infection in the subject.

14. The method of claim 11 , wherein administering the vaccine composition induces neutralizing responses against additional coronaviruses different from the coronaviruses the plurality of coronavirus antigens are of.

15. The method of claim 11 , wherein administering the vaccine composition induces neutralizing responses against the coronaviruses the plurality of coronavirus antigens are of.

16. The method of claim 12 , wherein administering the vaccine composition results in treating or preventing infection caused by additional coronaviruses different from the coronavirus the plurality of coronavirus antigens are of.

17. The method of claim 12 , wherein administering the vaccine composition results in treating or preventing infection caused by the coronaviruses the plurality of coronavirus antigens are of.

18. The method of claim 11 , wherein administering the vaccine composition comprises administering to the subject a first vaccine composition and administering to the subject a second vaccine composition.

19. The method of claim 18 , wherein administering to the subject the second vaccine composition occurs about two, three, or four weeks after administering to the subject the first vaccine composition.

20. The vaccine composition of claim 1 , wherein the plurality of coronavirus antigens further comprises a third coronavirus antigen of a third coronavirus strain and a fourth coronavirus antigen of a fourth coronavirus strain, and wherein the first, second, third, and fourth coronavirus strains are different from one another and selected from the group consisting of: SARS-COV, SARS-COV-2, WIV1, SHC014, Rf1, RmYN02, pang17, RaTG13, Rs4081, Yun11, BM-4831, and BtKY72.

21. The vaccine composition of claim 5 , wherein the third and fourth coronavirus antigens each comprise (1) an amino acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12; or (2) an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12, and wherein the amino acid sequences of the first, second, third and fourth coronavirus antigens are different from one another.

22. The vaccine composition of claim 21 , wherein the first, second, third, and fourth coronavirus antigens each comprise an amino acid sequence having at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12.

23. The vaccine composition of claim 21 , wherein the first, second, third, and fourth coronavirus antigens each comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12.

24. The vaccine composition of claim 1 , wherein the plurality of coronavirus antigens further comprise at least a third coronavirus antigen of a third coronavirus strain, a fourth coronavirus antigen of a fourth coronavirus strain, a fifth coronavirus antigen of a fifth coronavirus strain, a sixth coronavirus antigen of a sixth coronavirus strain, a seventh coronavirus antigen of a seventh coronavirus strain, and an eighth coronavirus antigen of an eighth coronavirus strain, the first, second, third, fourth, fifth, sixth, seventh, and eighth coronavirus antigens each comprising an amino acid sequence having at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12, and wherein the amino acid sequences of the first, second, third, fourth, fifth, sixth, seventh and eighth coronavirus antigens are different from one another.

25. The vaccine composition of claim 1 , wherein the first coronavirus strain and the second coronavirus strains are from different clades.

26. The vaccine composition of claim 1 , wherein the self-assembling nanoparticle is an i301 nanoparticle or a variant thereof, or a mi3 nanoparticle or a variant thereof.

27. A vaccine composition, comprising a multivalent carrier associated with a plurality of coronavirus antigens, wherein the plurality of coronavirus antigens comprises a first coronavirus antigen of a first coronavirus strain, a second coronavirus antigen of a second coronavirus strain, a third coronavirus antigen of a third coronavirus strain and a fourth coronavirus antigen of a fourth coronavirus strain, and wherein the first, second, third, and fourth coronavirus strains are different from one another and selected from the group consisting of: SARS-COV, SARS-COV-2, WIV1, SHC014, Rf1, RmYN02, pang17, RaTG13, Rs4081, Yun11, BM-4831, and BtKY72,

wherein the first coronavirus antigen and the second coronavirus antigen each comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12 and the amino acid sequences of the first and second coronavirus antigens are different from one another.

28. The vaccine composition of claim 27 , wherein the first coronavirus antigen and the second coronavirus antigen each comprise ( 1 ) an amino acid sequence having at least 85%, 90%, 95%, 98%, or 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12; or (2) an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12.

29. The vaccine composition of claim 27 , further comprising an adjuvant.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2022
From: COHEN, ALEXANDER A.; BJORKMAN, PAMELA J.
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 060142/0480 →
Continuity (2)
Provisional Application 63112495 · Nov 11, 2020
Related Publication 20220168414A1 · Jun 2, 2022
References Cited (80)
US 11964012B2 · Rauch · 2024 [cited by examiner]
US 20040022840A1 · Nagy · 2004 [cited by examiner]
US 20060286124A1 · Burt · 2006 [cited by examiner]
US 20180245052A1 · Egorov · 2018 [cited by examiner]
WO WO2007053188 · 2007 [cited by applicant]
Arora, Kajal, et al. “Multi-Antigenic Virus-like Particle of SARS CoV-2 produced in [cited by applicant]
Guo, Jingjing, et al. “Immunogenicity of a virus-like-particle vaccine containing multiple antigenic epitopes of toxoplasma gondii against acute and chronic toxoplasmosis in mice.” Frontiers in immunology 10 (2019): 592. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2021/058856, mailed on May 16, 2023, 6 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2021/058856 mailed on Mar. 8, 2022, 11 pages. [cited by applicant]
Shin, Matthew D., et al. “COVID-19 vaccine development and a potential nanomaterial path forward.” Nature nanotechnology 15.8 (2020): 646-655. [cited by applicant]
Xu, Ruodan, et al. “Construction of SARS-CoV-2 virus-like particles by mammalian expression system.” Frontiers in bioengineering and biotechnology 8 (2020): 862. [cited by applicant]
Altschul et al., “Basic Local Alignment Search Tool,” Journal of Molecular Biology 1990, 215, 403-410. [cited by applicant]
Andersen et al., “The proximal origin of SARS-CoV-2,” Nature Medicine 2020, 26, 450-455. [cited by applicant]
Angeletti et al., “Defining B Cell Immunodominance to Viruses,” Nature Immunology 2017, 18(4), 456-463. [cited by applicant]
Baker et al., “Structures of bovine and human papillomaviruses,” Biophysical Journal 1991, 60, 1445-1456. [cited by applicant]
Barnes et al., “SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies,” Nature 2020, 588, 682-703. [cited by applicant]
Barnes et al., “Structures of Human Antibodies Bound to SARSCoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies,” Cell 2020, 182, 828-842. [cited by applicant]
Brouwer et al., “Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability,” Science 2020, 369, 643-650. [cited by applicant]
Brune & Howarth, “New Routes and Opportunities for Modular Construction of Particulate vaccines: Stick, Click, and Glue,” Frontiers in Immunology 2018, 9(1432), 1-15. [cited by applicant]
Brune et al., “Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization,” Scientific Reports 2016, 6(19234), 1-13. [cited by applicant]
Bruun et al., “Engineering a Rugged Nanoscaffold to Enhance Plug-and-Display Vaccination,” ACS Nano 2018, 12, 8855-8866. [cited by applicant]
Cao et al., “Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells,” Cell 2020, 182, 73-84. [cited by applicant]
Cohen et al., “Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers,” PloS One 2021, 16(3), e0247963, 1-24. [cited by applicant]
Cohen et al., “Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice,” Science 2021, 371, 735-741. [cited by applicant]
Corpet, “Multiple sequence alignment with hierarchical clustering,” Nucleic Acids Research 1988, 16(22), 10881-10890. [cited by applicant]
Crawford et al., “Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assay,” Viruses 2020, 12(513), 1-15. [cited by applicant]
Fung & Liu, “Human Coronavirus: Host-Pathogen Interaction,” Annual Review of Microbiology 2019, 73, 529-557. [cited by applicant]
Gristick et al., “Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site,” Nature Structural Biology 2016, 32(10), 906-915. [cited by applicant]
Hagensee et al., “Three-Dimensional Structure of Vaccinia Virus-Produced Human Papillomavirus Type 1 Capsids,” Journal of Virology 1994, 68(7), 4503-4505. [cited by applicant]
Higgins & Sharp, “Clustal: a package for performing multiple sequence alignment on a microcomputer,” Gene 1988, 73, 237-244. [cited by applicant]
Higgins & Sharp, “Fast and sensitive multiple sequence alignments on a microcomputer,” Cabios Communications 1989, 5(2), 151-153. [cited by applicant]
Hoffman et al., “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is Blocked by a Clinically Proven Protease Inhibitor,” Cell 2020, 181, 1-10. [cited by applicant]
Holmes. “Coronaviruses,” Academic Press 1999, 291-298. [cited by applicant]
Hsieh et al., “Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes,” bioRxiv 2020, in 39 pages. https://doi.org/10.1101/2020.05.30.125484. [cited by applicant]
Hu et al., “Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus,” PLoS Pathogens 2017, 13(11), e1006698, 1-27. [cited by applicant]
Huang et al., “Human Coronavirus HKU1 Spike Protein Uses O-Acetylated Sialic Acid as an Attachment Receptor Determinant and Employs Hemagglutinin-Esterase Protein as a Receptor-Destroying Enzyme,” Journal of Virology 20… [cited by applicant]
Kanekiyo et al., “Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses,” Nature Immunology 2019, 20(3), 362-372. [cited by applicant]
Keeble et al., “Approaching infinite affinity through engineering of peptide-protein interaction,” PNAS 2019, 116(52), 26523-26533. [cited by applicant]
Kreer et al., “Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients,” Cell 2020, 182, 843-854. [cited by applicant]
Lam et al., “Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins,” Nature 2020, 583, 282-298. [cited by applicant]
Lan et al., “Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor,” Nature 2020, 581, 215-220. [cited by applicant]
Landau et al., “ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures,” Nucleic Acids Research 2005, 33, W299-W302. [cited by applicant]
Leist et al., “A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice,” Cell 2020, 183, 1070-1085. [cited by applicant]
Letko et al., “Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses,” Nature Microbiology 2020, 5, 562-569. [cited by applicant]
Li et al., “Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus,” Nature 2003, 426, 450-454. [cited by applicant]
Li et al., “Bats Are Natural Reservoirs of SARS-Like Coronaviruses,” Science 2005, 310, 676-679. [cited by applicant]
Liu et al., “Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike,” Nature 2020, 584, 450-475. [cited by applicant]
López-Sagaseta et al., “Self-assembling protein nanoparticles in the design of vaccines,” Computational and Structural Biotechnology Journal 2016, 14, 58-68. [cited by applicant]
Menachery et al., “A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence,” Nature Medicine 2015, 21(12), 1508-1515. [cited by applicant]
Menachery et al., “SARS-like WIV1-CoV poised for human emergence,” PNAS 2016, 113(11), 3048-3053. [cited by applicant]
Needleman & Wunsch, “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,” Journal of Molecular Biology 1970, 48, 443-453. [cited by applicant]
Pearson & Lipman, “Improved tools for biological sequence comparison,” PNAS 1988, 85, 2444-2448. [cited by applicant]
Piccoli et al., “Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology,” Cell 2020, 183, 1024-1042. [cited by applicant]
Pinto et al., “Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody,” Nature 2020, 583, 290-312. [cited by applicant]
Rahikainen et al., “Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation,” Angewandte Chemie International Edition 2021, 60, 321-330. [cited by applicant]
Raj et al., “Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC,” Nature 2013, 495, 251-254. [cited by applicant]
Rambaut et al., “Preliminary genomic characterisation of an emergentSARS-CoV-2 lineage in the UK defined by a novel set of spike mutations,” ARTIC Network 2020, in 9 pages. [cited by applicant]
Robbiani et al., “Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals.” Nature 2020, 584(7821), 437-442. [cited by applicant]
Rogers et al., “Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model,” bioRxiv 2020, in 10 pages. https://doi.org/10.1101/2020.05.11.088674. [cited by applicant]
Schmidt et al., “Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses,” Journal of Experimental Medicine 2020, 217(11), e20201181, 1-18. [cited by applicant]
Seydoux et al., “Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation,” Immunity 2020, 53, 98-105. [cited by applicant]
Shi et al., “A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2,” Nature 2020, 584, 120-142. [cited by applicant]
Slifka & Amanna, “Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses,” Frontiers in Immunology 2019, 10(956), 1-16. [cited by applicant]
Smith, “Comparison of Biosequences,” Advances in Applied Mathematics 1981, 2, 482-489. [cited by applicant]
Tan et al., “A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses,” Nature Communications 2021, 12(542), 1-… [cited by applicant]
Tao & Tong, “Complete Genome Sequence of a Severe Acute Respiratory Syndrome-Related Coronavirus from Kenyan Bats,” Microbiology Resource Announcements 2019, 8(28), e00548-19, 1-5. [cited by applicant]
Van Dorp et al., “Recurrent mutations in SARS-CoV-2 genomes isolated from mink point to rapid host-adaptation,” bioRxiv 2020, preprint, 1-27. https://doi.org/10.1101/2020.11.16.384743. [cited by applicant]
Vlasak et al., “Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses,” PNAS 1988, 85, 4526-4529. [cited by applicant]
Walls et al., “Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2,” Cell 2020, 183, 1367-1382. [cited by applicant]
Wang et al., “Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China,” Virologica Sinica 2018, in 4 pages. [cited by applicant]
West et al., “Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues,” PNAS 2013, 110(26), 10598-10603. [cited by applicant]
Wit et al., “SARS and MERS: recent insights into emerging coronaviruses,” Nature Reviews 2016, 14, 523-534. [cited by applicant]
Wu et al., “A new coronavirus associated with human respiratory disease in China,” Nature 2020, 579, 265-269. [cited by applicant]
Zakeri et al., “Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin,” PNAS 2012, E690-E697. [cited by applicant]
Zhang et al., “A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone,” Scientific Rep… [cited by applicant]
Zhou et al., “A Novel Bat Coronavirus Closely Related to SARSCoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein,” Current Biology 2020, 30, 2196-2203. [cited by applicant]
Zhou et al., “A pneumonia outbreak associated with a new coronavirus of probable bat origin,” Nature 2020, 579, 270-273. [cited by applicant]
Zost et al., “Potently neutralizing and protective human antibodies against SARS-CoV-2,” Nature 2020, 584(7821), 443-449. [cited by applicant]
Zost et al., “Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,” Nature Medicine 2020, 26(9), 1422-1427. [cited by applicant]
Extended European Search Report dated Aug. 28, 2024 in European Patent Application No. 21892767.1. [cited by applicant]